@Article{ecn.2018.0406,
AUTHOR = {Shi-Min Yuan},
TITLE = {Interleukin-6 and cardiac operations},
JOURNAL = {European Cytokine Network},
VOLUME = {29},
YEAR = {2018},
NUMBER = {1},
PAGES = {1--15},
URL = {http://www.techscience.com/ECN/v29n1/65407},
ISSN = {1952-4005},
ABSTRACT = {Interleukin (IL)-6 is a pleiotropic inflammatory cytokine with both pro- and anti-inflammatory capacities,
produced by different cells and tissues, such as leukocytes, adipocytes, and endothelium. From the viewpoint
of cardiologists, this cytokine is a reliable biomarker of cardiac dysfunction, occurrence of atrial fibrillation, cardiac
myxoma with recurrence, remote metastasis or embolization, and atherosclerotic processes. Although IL-6
levels were detected in patients undergoing cardiac operations and reported sporadically, the perioperative kinetics
of IL-6 in cardiac surgical patients was insufficiently elaborated. The influencing factors, clinical implications,
and causative effects of IL-6 on clinical outcomes and potential treatment choices among cardiac surgical patients
remained to be clarified as well. The purpose of this article is to discuss these aspects of IL-6 in patients undergoing
a cardiac operation.},
DOI = {10.1684/ecn.2018.0406}
}